SCHEMBL8098487

SCHEMBL8098487

Cc1ccc(Nc2cc(N(C)C)nc(CCCc3cccs3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.42
LMNA P02545 6/20 0.38
MAPT P10636 5/20 0.37
KDM4E B2RXH2 3/20 0.37
HTT P42858 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
USP2 O75604 1/20 0.37
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
GAA P10253 2/20 0.36
TP53 P04637 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
POLB P06746 1/20 0.34
GBA1 P04062 1/20 0.34
PYGM P11217 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240585 0.83 ADORA3 (0.44) METAP2LMNAMAPTKDM4EHTT
SCHEMBL8088282 0.80 MAPT (0.50) METAP2LMNAMAPTKDM4EHTT
SCHEMBL8098432 0.76 MAPT (0.44) LMNAMAPTKDM4EHTTNPSR1
SCHEMBL3785990 0.74 MAPT (0.47) METAP2LMNAMAPTKDM4EALDH1A1
SCHEMBL2411151 0.70 TAAR1 (0.58) LMNAMAPTKDM4EHTTNPSR1
SCHEMBL3243396 0.68 NUDT1 (0.58) LMNAMAPTNPC1RAB9AGAA
SCHEMBL29609269 0.68 NUDT1 (0.58) LMNAMAPTNPC1RAB9AGAA
SCHEMBL8524757 0.67 MEN1 (0.44) LMNAMAPTKDM4EHTTNPSR1
SCHEMBL3244336 0.67 MAPT (0.57) LMNAMAPTKDM4EHTTNPSR1
SCHEMBL8253278 0.66 MAPT (0.74) LMNAMAPTKDM4EHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220775-B2 Compound useful for the treatment of neuropathic pain H. LUNDBECK A/S (DK) 2007-05-22 US disclosed
US-7220775-B2 Compound useful for the treatment of neuropathic pain H. LUNDBECK A/S (DK) 2007-05-22 US disclosed
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2004-05-13 US disclosed
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain GALR3, GALR2, GALR1 METAP2 2263/4885LMNA 2883/4885MAPT 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.